Rare disease biotech firms expand teams as FDA approvals boost pipelines

Several biotech companies focused on rare diseases are actively hiring, offering opportunities for professionals interested in this niche therapeutic area. The article highlights four firms that are advancing drugs toward market approval and currently have open positions.

One of the companies, Scholar Rock, recently received FDA approval for its monoclonal antibody Isembyld to treat spinal muscular atrophy in patients aged two years and older who are also on SMN2‑targeted therapy. The biotech, which uses a platform to target protein growth factors, lists about 30 job openings across various functions.

The hiring surge reflects the momentum generated by recent regulatory successes and the ongoing need for talent to support drug development pipelines in rare diseases, making these firms attractive prospects for job seekers and investors alike.